An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on? Biosimilar watchers circled 2023 as a red-letter year because that was the year that the Humira ...

While speaking at the conference, J&J’s CEO, Joaquin Duato, indicated the company’s willingness to protect Stelara, its branded anti-interleukin (IL)-12/23 biologic, against sales erosion from ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

Vigorous protection of Stelara’s position aligns with a strategy to grow in the immunology space. Credit: josefkubes via Shutterstock. During its presentation at the JP Morgan Healthcare Conference ...

The biosimilar, referencing Johnson & Johnson’s (NYSE: JNJ) Stelara, targets inflammatory conditions such as Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously ...